This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Trimoulet, P.
Right arrow Articles by Fleury, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Trimoulet, P.
Right arrow Articles by Fleury, H.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, June 2002, p. 2031-2036, Vol. 40, No. 6
0095-1137/02/$04.00+0     DOI: 10.1128/JCM.40.6.2031-2036.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Evaluation of the VERSANT HCV RNA 3.0 Assay for Quantification of Hepatitis C Virus RNA in Serum

Pascale Trimoulet,1* Philippe Halfon,2 Eric Pohier,3 Hacène Khiri,2 Geneviève Chêne,3 and Hervé Fleury1

Laboratoire de Virologie, Centre Hospitalier Régional et Université Victor Segalen,1 Unité d'Epidémiologie Clinique, CHU de Bordeaux, Bordeaux,3 Laboratoire Alphabio, Marseille, France2

Received 2 November 2001/ Returned for modification 24 December 2001/ Accepted 14 March 2002

We assessed the performance of a new assay (VERSANT HCV RNA 3.0 [bDNA 3.0] assay [Bayer Diagnostics]) to quantitate HCV RNA levels and compared the results of the bDNA 3.0 assay to results of the Quantiplex HCV RNA 2.0 (bDNA 2.0) assay. Samples used in this study included 211 serum specimens from hepatitis C virus (HCV)-infected persons from two sites (Bordeaux and Marseille, France) with different genotypes; 383 serum specimens from HCV antibody-negative, HCV RNA-negative persons; and serial dilutions of World Health Organization (WHO) HCV RNA standard at a titer of 100,000 IU/ml. The specificity of the bDNA 3.0 assay was 98.2%. A high correlation was observed between expected and observed values in all dilutions of WHO standard (r = 0.9982), in serial dilutions of pooled samples (r = 0.9996), and in diluted sera from different HCV genotypes (r = 0.9930 to 0.9995). The standard deviations (SD) for the within-run and between-run reproducibility of the bDNA 3.0 assay were <=0.2 and <=0.14, respectively. The intersite SD ranged from 0.03 to 0.14. The bDNA 3.0 assay results were positively correlated with the bDNA 2.0 assay results (r = 0.9533). Taking in account the overall performance, this assay could be used as a routine tool for the HCV RNA quantification.

* Corresponding author. Mailing address: Laboratoire de Virologie, Hôpital Pellegrin, Place Amélie Raba-Léon, 33076 Bordeaux, France. Phone: 33 5 56 79 55 10. Fax: 33 5 56 79 56 73. E-mail: pascale.trimoulet{at}chu-bordeaux.fr.

Journal of Clinical Microbiology, June 2002, p. 2031-2036, Vol. 40, No. 6
0095-1137/02/$04.00+0     DOI: 10.1128/JCM.40.6.2031-2036.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Chevaliez, S., Bouvier-Alias, M., Pawlotsky, J.-M. (2009). Performance of the Abbott Real-Time PCR Assay Using m2000sp and m2000rt for Hepatitis C Virus RNA Quantification. J. Clin. Microbiol. 47: 1726-1732 [Abstract] [Full Text]  
  • NJOUOM, R., PASQUIER, C., AYOUBA, A., TEJIOKEM, M. C., VESSIERE, A., MFOUPOUENDOUN, J., TENE, G., ETEKI, N., LOBE, M. M., IZOPET, J., NERRIENET, E. (2005). LOW RISK OF MOTHER-TO-CHILD TRANSMISSION OF HEPATITIS C VIRUS IN YAOUNDE, CAMEROON: THE ANRS 1262 STUDY. Am J Trop Med Hyg 73: 460-466 [Abstract] [Full Text]  
  • Desombere, I., Van Vlierberghe, H., Couvent, S., Clinckspoor, F., Leroux-Roels, G. (2005). Comparison of Qualitative (COBAS AMPLICOR HCV 2.0 versus VERSANT HCV RNA) and Quantitative (COBAS AMPLICOR HCV Monitor 2.0 versus VERSANT HCV RNA 3.0) Assays for Hepatitis C Virus (HCV) RNA Detection and Quantification: Impact on Diagnosis and Treatment of HCV Infections. J. Clin. Microbiol. 43: 2590-2597 [Abstract] [Full Text]  
  • Cook, L., Ng, K.-W., Bagabag, A., Corey, L., Jerome, K. R. (2004). Use of the MagNA Pure LC Automated Nucleic Acid Extraction System followed by Real-Time Reverse Transcription-PCR for Ultrasensitive Quantitation of Hepatitis C Virus RNA. J. Clin. Microbiol. 42: 4130-4136 [Abstract] [Full Text]  
  • Barbeau, J. M., Goforth, J., Caliendo, A. M., Nolte, F. S. (2004). Performance Characteristics of a Quantitative TaqMan Hepatitis C Virus RNA Analyte-Specific Reagent. J. Clin. Microbiol. 42: 3739-3746 [Abstract] [Full Text]  
  • Elbeik, T., Surtihadi, J., Destree, M., Gorlin, J., Holodniy, M., Jortani, S. A., Kuramoto, K., Ng, V., Valdes, R. Jr., Valsamakis, A., Terrault, N. A. (2004). Multicenter Evaluation of the Performance Characteristics of the Bayer VERSANT HCV RNA 3.0 Assay (bDNA). J. Clin. Microbiol. 42: 563-569 [Abstract] [Full Text]  
  • Morishima, C., Chung, M., Ng, K. W., Brambilla, D. J., Gretch, D. R. (2004). Strengths and Limitations of Commercial Tests for Hepatitis C Virus RNA Quantification. J. Clin. Microbiol. 42: 421-425 [Abstract] [Full Text]  
  • Tedeschi, R., Pivetta, E., Zanussi, S., Bidoli, E., Ros, M., di Gennaro, G., Nasti, G., De Paoli, P. (2003). Quantification of Hepatitis C Virus (HCV) in Liver Specimens and Sera from Patients with Human Immunodeficiency Virus Coinfection by Using the Versant HCV RNA 3.0 (Branched DNA-Based) DNA Assay. J. Clin. Microbiol. 41: 3046-3050 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»